Stock listing
Cognition Therapeutics, Inc.
Selected listing: CGTX · NASDAQ · USD · US
Cognition Therapeutics, Inc. (NASDAQ:CGTX), Health Technology. Latest release Sep 29, 2026: Cognition Therapeutics Schedules a Type C Meeting with FDA…
- Ticker
- NASDAQ:CGTX
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Cognition Therapeutics, Inc.
The company focuses on developing therapies for neurodegenerative diseases. Its innovative approach aims to address unmet medical needs in this critical area of healthcare.
Latest news from Cognition Therapeutics, Inc.
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
September 28, 2026
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
September 8, 2026
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
August 6, 2026
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
July 13, 2026
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
June 24, 2026
Events
Research Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. company profile
View the public company page for Cognition Therapeutics, Inc. on 6ix.
Cognition Therapeutics, Inc. news
Read company news and market updates connected to Cognition Therapeutics, Inc..
Cognition Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Cognition Therapeutics, Inc..